Adicet Bio Inc (NAS:ACET)
$ 1.44 -0.03 (-2.04%) Market Cap: 118.32 Mil Enterprise Value: -18.00 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 54/100

Adicet Bio Inc ASCO Update Call Transcript

Jun 06, 2022 / 08:30PM GMT
Release Date Price: $12.26 (+6.61%)
Unidentified Company Representative

Good afternoon, thank you for joining us. On the call today from Adicet are Chen Schor, President and CEO, Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer.

In addition, we're very pleased to have Dr. Sattva Neelapu professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center joining us today.

Before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking statements that are made under the safe harbor provisions of the securities laws, including, but not limited to, expressed or implied statements regarding the potential safety durability, tolerability and therapeutic effects of ADI-001, including the expected design, implementation, timing and success of ADI-001, plans and timing for the release of additional clinical data from Adicet's Phase I trial of ADI-001, in relapsed, refractory NHL patients, future progress of the GLEAN study, including ongoing patient enrollment expectations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot